Cantargia: Edison Open House Healthcare 2022

Cantargia: Edison Open House Healthcare 2022

Cantargia — 8 videos in collection

More on this equity

Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on NSCLC and pancreatic cancer. The most advanced trial is in Phase II.

• Please explain the link between cancer, autoimmune and inflammatory disorders.
• How does CAN04 differ from other treatments?
• What results have you seen in recent CAN04 tests?
• What is your R&D strategy for nadunolimab?
• What data should we expect and when?
• How does your other asset, CAN10, which has an autoimmune focus, fit in your plans?


You may also be interested in these:

Healthcare

Cantargia - executive interview

Healthcare

Cantargia – executive interview

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.